Skip to content


Duavee, Conbriza (bazedoxifene) is a small molecule pharmaceutical. Bazedoxifene was first approved as Duavee on 2009-04-17. It is used to treat menopause in the USA. It has been approved in Europe to treat postmenopausal osteoporosis. The pharmaceutical is active against estrogen receptor beta and estrogen receptor. Duavee's patent is valid until 2027-03-10 (FDA).
Trade Name Conbriza
Common Name Bazedoxifene
Indication menopause, postmenopausal osteoporosis
Drug Class Antiestrogens of the clomifene and tamoxifen groups
Get full access now